Latest news with #IMAN
Irish Independent
31-07-2025
- Business
- Irish Independent
Two Galway medical projects awarded €20million
The Disruptive Technologies Innovation Fund (DTIF) has invested €422 million so far into progressing the six national research priority areas: ICT, health and wellbeing, food, energy, climate action and sustainability, manufacturing and materials, and services and business processes. It is also one of the four funds set up in the National Development Plan through 2027. 'The Disruptive Technologies Innovation Fund is about investing in bold ideas and ambitious partnerships that have the potential to deliver real impact – for our economy and for our society, said Enterprise Ireland CEO, Jenny Melia. Of the almost half a million euro awarded thus far, 34pc (€132 million) of that has been to projects in County Galway. The scheme has received a total of 299 funding applications, with only 110 approved nationwide to date. Thus far in Galway, all applications submitted during the seventh call have been successful. The remaining applications are still under review, with another call for submissions expected later this year. The first project, N-LIFT, received €12 million, the largest sum of money, to 'overcome treatment resistance in advanced or metastatic solid tumours that are no longer responding to therapy'. This includes specifically metastatic cervical cancer and head and neck cancer. In collaboration between the University of Galway, LIfT BioSciences, and Hooke Bio the funds will help launch the first human trial of Immunomodulatory Alpha Neutrophils (IMAN) therapy. 'Starting human studies brings us closer to clinically validating this approach and lays the groundwork for expanding our operations in Ireland, attracting further investment, and accelerating development of what we believe could be a game-changing cancer therapy,' said CEO of LIfT Biosciences, Alex Blyth. 'The results from scans, biopsies and bloods will enable us to see the effect the treatment is having, and, in particular, how 'hot' we have made the tumour in terms IMANs recruiting and activating patients own immune cells to help attack the tumour – an early indicator of this working.' LIfT is an Irish-based biotech company with offices in An Spidéal. CEO of Údarás na Gaeltachta, Tomás Ó Síocháin calls on the 'tremendous potential' of how 'international biotechnology companies can thrive in Gaeltacht communities while creating high-value employment opportunities'. An expanded workforce in An Spidéal is expected as it moves towards the clinical trial start date in 2026. ADVERTISEMENT The second project to be awarded €9 million in funds is Ventripump seeking to treat cardiogenic shock – a life-threatening condition where the heart fails to pump enough blood to meet the needs of the body. The goal is to bring the device platform up as the 'gold standard' in the medical industry. The team behind this initiative includes CardiacBooster, Integer Holdings, and Fire1, who aim to deliver the 'first significant innovation' for a condition with a notably high mortality rate. The core objective of both is preventing loss of life and enhancing the quality of it. Funded by the Local Democracy Reporting Scheme.
Yahoo
04-06-2025
- Business
- Yahoo
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
LIfT BioSciences joins Bayer Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. 'We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Cambridge at Bayer HealthCare LLC said: 'The was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.' As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@ in to access your portfolio
Yahoo
04-06-2025
- Business
- Yahoo
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
LIfT BioSciences joins Bayer Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. 'We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Cambridge at Bayer HealthCare LLC said: 'The was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.' As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
04-06-2025
- Business
- Business Upturn
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
LIfT BioSciences joins Bayer Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. ' We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Cambridge at Bayer HealthCare LLC said: 'The was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.' As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciences LIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further information Investors: Alex Blyth [email protected]
Yahoo
04-06-2025
- Business
- Yahoo
LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities
LIfT BioSciences joins Bayer Cambridge, securing access to cutting-edge lab facilities London, 4 June 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into a license agreement with Bayer HealthCare LLC, granting LIfT access to Bayer's state-of-the-art facilities in Cambridge, Massachusetts – one of the world's leading hubs for biotech innovation. This agreement provides LIfT with advanced infrastructure and shared services in a highly collaborative research environment, accelerating the development of its Immuno-Modulatory Alpha Neutrophil (IMAN) platform designed to overcome treatment resistance in solid tumours. 'We see a strong strategic fit with The Bayer Group who have supported using cell therapies to replace dysfunctional cell types in the body in other therapeutic settings, and have developed the world-class facilities and expertise to cost-effectivenely deliver those therapies that we can now look to benefit from. The Bayer offers a unique environment designed to support our kind of biotech innovation, and strengthen our transatlantic presence as we expand as a clinical stage company,' said Alex Blyth, Chief Executive Officer of LIfT Biosciences. Fiona Mack, Head Cambridge at Bayer HealthCare LLC said: 'The was created to provide cutting-edge biotech companies with the space, resources and network they need to accelerate their research and development. portfolio companies have been selected by a panel of experts within Bayer based upon the scientific merit and potential to substantially impact healthcare. LIfT, with its novel immunotherapy approach, exemplifies the type of company and innovative science that we aim to support and we believe they will be a great fit in our collaborative environment.' As part of the agreement, LIfT will gain access to a cutting-edge innovation space designed to support the unique needs of early-stage biotechs, with the flexibility to expand into larger 'pods' or private lab areas as operations grow. LIfT will also benefit from centralised procurement and operational support, enabling the team to focus on advancing its IMAN platform efficiently and safely. About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See Further informationInvestors:Alex Blyth ablyth@ Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@ 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
